arrow
C

Cristina Gil

hospital general universitario de alicante
H指数:21
被引数:1,191

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
2026-09-010
OAAI
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Gilteritinib在二线治疗后的有效性:一项关于171例复发/难治性FLT3突变急性髓系白血病患者的真实世界多中心研究

2025-11-010
OAAI
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

自体或异基因造血干细胞移植作为成人继发性急性髓系白血病患者的首线治疗:PETHEMA登记研究经验

2025-02-010
PRE
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
2024-08-080
OAAI
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
2023-05-184
OAAI
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
2023-05-128
OAAI
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
2023-01-010
OAAI
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
2022-07-117
OAAI
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
2022-06-094
OAAI
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
2022-02-1737
OAAI
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
LEUKEMIA
IF13.4
2021-11-160
OAAI
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
LEUKEMIA
IF13.4
2021-11-1338
OAAI
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
2021-10-2016
OAAI
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
2021-08-0522
OAAI
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
CANCER
IF5.1
2021-02-2418
OAAI
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
2021-02-0318
OA
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
LEUKEMIA
IF13.4
2020-10-1919
PREAI